The Chinese Center for Disease Control and Prevention has recorded that Omicron lineages BA.5.2 and BF.7 account for 97.5% of all local infections in the country.
New cases are spreading rapidly and the National Health Commission (NHC) has announced a national vaccination campaign for people to receive a fourth dosage.
The result of the situation is that Chinese vaccine developers are focused on expanding their COVID-19 pipelines to incorporate jabs that have the ability to tackle new variants, according to GlobalData.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze